Big Pharma is poised for growth due to strong launch portfolios, the availability of high-potential pipeline assets, and companies’ sharpened focus on highperforming markets This report explores and visualizes market dynamics in the Big Pharma peer set out to 2024, using in-house sales forecasts By delving deeper into drivers of strategy, revenue trends, and therapy area focus, this analysis is vital to understanding how the industry will navigate headwinds in order to steer towards robust growth
What’s included in this report:
Therapy Area Analysis
Key questions answered:
What are the significant challenges and drivers facing Big Pharma out to 2024?
Which companies will propel revenue growth over the forecasts period?
Which companies will have leading market share gains and market share losses?
How are late stage pipelines positioned, and what are the most-coveted launch products?
Which therapy areas will experience the largest growth and decline?
What are the portfolio weightings of Big Pharma based on the lifecycle of products?
How is Big Pharma adopting lifecycle management strategies to increase value?
Our reports have been used by over 10K customers, including:
Post Menopausal Osteoporosis - Pipeline Review, H1 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Post Menopausal Osteoporosis - Pipeline Review, H1 2020, provides an overview of the Post Menopausal Osteoporosis (Metabolic Disorders) pipeline landscape. Postmenopausal...
Oncology Biosimilars Market Research Report by Application (Cancer Treatment Drugs and Supportive Care Drugs), by End-User (Hospitals and Retail Pharmacies) - Global Forecast to 2025 - Cumulative Impact of COVID-19 The Global Oncology Biosimilars Market is expected to grow from USD 2,434.01 Million in 2019 to USD 6,262.20...
The immunotherapy drugs market is projected to grow at a CAGR of 11.0% during the forecast period (2020–2025). The global immunotherapy drugs market is projected to reach USD 274.6 billion by 2025 from USD 163.0 billion in 2020, at a CAGR of 11.0 % during the forecast period. Market growth is primarily driven by the rising demand for immunotherapies...